Alterations in the Gut Microbiome and Suppression of Histone Deacetylases by Resveratrol Are Associated with Attenuation of Colonic Inflammation and Protection Against Colorectal Cancer

• DOI: 10.3390/jcm9061796
• Publication Date: 2020-06-09T12:49:11Z
• Authors: Haider Rasheed Al...; Philip Brandon Bu...; Kumaraswamy Naidu...; Mitzi Nagarkatti; Prakash Nagarkatti
• Keywords: Sodium butyrate; Proinflammatory cytokine; Metabolome

Inflammatory bowel disease (IBD) is known to significantly increase the risk for development of colorectal cancer (CRC), suggesting inflammation and are closely intertwined. Thus, agents that suppress may prevent onset cancer. In current study, we used resveratrol, an anti-inflammatory stilbenoid, study role microbiota in preventing inflammation-driven CRC. Resveratrol treatment azoxymethane (AOM) dextran sodium sulphate (DSS) CRC murine model caused CD4 + FOXP3 (Tregs) IL10 cells, a decrease proinflammatory Th1 Th17 attenuated development. Gut microbial profile studies demonstrated resveratrol altered gut microbiome short chain fatty acid (SCFA), with modest increases n-butyric potential butyrate precursor isobutyric acid. Fecal transfer from resveratrol-treated mice supplementation resulted attenuation suppression inflammatory T cell response. Data also revealed both (BUT) were capable inhibiting histone deacetylases (HDACs), correlating Treg induction. Analysis The Cancer Genome Atlas (TCGA) datasets increased expression Treg-specific transcription factor FoxP3 or IL-10 5-year survival patients These data suggest alterations lead response, leading